StemCells Inc. Closes Enrollment In Phase I/II Dry AMD Trial - Quick Facts

(RTTNews) - StemCells, Inc. (STEM) Friday announced that, it has closed enrollment in its Phase I/II clinical trial for dry age-related macular degeneration or AMD for focussing its attention on a follow-on Phase II randomized, controlled proof-of-concept study, later this year. Interim results for the AMD trial showed a 70 percent reduction in the rate of geographic atrophyor or GA compared with the control eye and a 65 percent reduction in the rate of GA compared with the expected natural history of the disease following a single dose of the company's proprietary HuCNS-SC human neural stem cells. The trial has also showed a favorable safety profile for HuCNS-SC as a treatment for dry AMD. Final results are expected to be released during mid-2015.